Holen Sie sich die Stockscreener-App
12.25
6.83%
0.76
Schlusskurs vom Vortag:
$11.49
Offen:
$11.27
24-Stunden-Volumen:
112.00K
Relative Volume:
0.42
Marktkapitalisierung:
$155.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+12.72%
1M Leistung:
-13.62%
6M Leistung:
-76.69%
1J Leistung:
-59.74%
1-Tages-Spanne:
$11.27
$13.09
1-Wochen-Bereich:
$10.46
$13.09
52-Wochen-Spanne:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Vergleichen Sie NGNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
12.39 | 155.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.75 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.78 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.54 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.40 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.75 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-21 | Eingeleitet | William Blair | Outperform |
| 2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-05 | Eingeleitet | Stifel | Buy |
| 2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Wellington Management Group LLP Grows Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - The AM Reporter
BMO cuts Neurogene stock target to $16 from $45, keeps Outperform By Investing.com - Investing.com South Africa
Wellington Management Group LLP Increases Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - Defense World
JPMorgan Chase & Co. Purchases 476,418 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene (NASDAQ:NGNE) Given New $16.00 Price Target at BMO Capital Markets - Defense World
Neurogene Inc. Amends Agreement, Issues Warrants By Investing.com - Investing.com South Africa
Neurogene Inc. Amends Agreement, Issues Warrants - Investing.com
Neurogene Amends Agreement With Baker Bros To Increase Nomination Threshold - marketscreener.com
BMO cuts Neurogene stock target to $16 from $45, keeps Outperform - Investing.com Canada
NGNE stock touches 52-week low at $8.35 amid market challenges - Investing.com Australia
NGNE stock touches 52-week low at $8.35 amid market challenges By Investing.com - Investing.com South Africa
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome - BioSpace
Neurogene reports progress in gene therapy regulation technology By Investing.com - Investing.com Canada
Neurogene reports progress in gene therapy regulation technology - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation - ACCESS Newswire
Q1 Earnings Estimate for Neurogene Issued By HC Wainwright - The AM Reporter
What is Leerink Partnrs’ Forecast for Neurogene Q1 Earnings? - Defense World
Neurogene Inc. (NASDAQ:NGNE) Receives $59.80 Average PT from Brokerages - Defense World
What is William Blair’s Forecast for Neurogene Q1 Earnings? - Defense World
What is HC Wainwright’s Estimate for Neurogene Q1 Earnings? - Defense World
Neurogene Reports 2024 Financial Results and Advances in Rett Syndrome Trial - MSN
PNC Financial Services Group Inc. Makes New $71,000 Investment in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Neurogene (NASDAQ:NGNE) Receives Outperform Rating from William Blair - Defense World
Stifel maintains Buy on Neurogene stock with $46 target By Investing.com - Investing.com UK
Neurogene (NASDAQ:NGNE) Given New $50.00 Price Target at HC Wainwright - Defense World
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates - BioSpace
Neurogene Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Neurogene Inc. (NGNE) reports earnings - Quartz
Neurogene Inc Files For Mixed Shelf Offering Of Up To $300 MillionSEC Filing -March 24, 2025 at 04:38 pm EDT - MarketScreener
Neurogene Inc (NASDAQ: NGNE): Overvalued Compared To Others? - Stocks Register
Insiders Re-Evaluate Their US$1.46m Stock Purchase As Neurogene Falls To US$251m - simplywall.st
NEUROGENE Earnings Preview: Recent $NGNE Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rhumbline Advisers Buys 1,326 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401 - Seeking Alpha
Neurogene (NASDAQ:NGNE) Shares Down 8.4% – Here’s Why - Defense World
Neoleukin Therapeutics, Inc. Announces Reduction in the Workforce -March 08, 2023 at 05:00 pm EST - marketscreener.com
Neurogene to Participate in Upcoming Conferences - Business Wire
Can These 3 Healthcare Conferences Reveal Neurogene's Next Big Move? - Stock Titan
Neurogene Insiders Placed Bullish Bets Worth US$1.46m - Yahoo Canada Finance
Neurogene (NGNE) to Release Quarterly Earnings on Monday - Defense World
Neurogene (NGNE) Projected to Post Quarterly Earnings on Monday - MarketBeat
Neurogene Inc (NGNE) Shares Decline Despite Market Challenges - The News Heater
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect - accessnewswire.com
Should You Expect Neurogene Inc (NASDAQ:NGNE) To Recover From Its 38.11% Gain From Highs? - Marketing Sentinel
Get in on Neurogene Inc’s (NGNE) buy-in window today! - SETE News
Neurogene Inc [NASDAQ: NGNE] Sees Increase in Stock Value - Knox Daily
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Neurogene Inc (NGNE) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Neurogene Inc-Aktie (NGNE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Samsara BioCapital GP, LLC | 10% Owner |
Nov 26 '24 |
Buy |
25.83 |
48,770 |
1,259,623 |
1,717,127 |
| Cvijic Christine Mikail | President and CFO |
Nov 22 '24 |
Buy |
20.48 |
24,000 |
491,400 |
76,844 |
| McMinn Rachel | Chief Executive Officer |
Nov 22 '24 |
Buy |
20.40 |
47,500 |
969,000 |
1,297,859 |
0.77%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):